Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period of 16 weeks.

Trial Profile

Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period of 16 weeks.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2012

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2012 Planned number of patients changed from 540 to 640 as reported by European Clinical Trials Database.
    • 28 Jun 2012 Actual initiation date changed from 19 Feb 2010 to 12 Jan 2010 and additional locations added as reported by European Clinical Trials Database.
    • 28 Jun 2012 Actual end date (12 Jan 2012) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top